Combining EGFR-targeted delivery with albumin-based nanocarriers thus offers a powerful dual strategy: the targeting ligand directs the carrier to EGFR-overexpressing tumor sites, while albumin ensures stability, biodegradability, and efficient intracellular transport. This evidence concerns the gene EGFR and neoplasm.